Evidence map›Paper›PMID 20663135›Full record

ArticleBMC cancer2010

Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.

Janka Teutschbein, Johannes M Haydn, Birgit Samans, Michael Krause, Martin Eilers, Manfred Schartl, Svenja Meierjohann

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Investigating the Role of DUSP4 in Uveal Melanoma.Translational vision science & technology · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. NRF2 Enables EGFR Signaling in Melanoma Cells.International journal of molecular sciences · 2021
    Article
  9. Review
  10. Expression signatures of early-stage and advanced medaka melanomas.Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Janka TeutschbeinDepartment of Physiological Chemistry I, Biocenter, University of Wurzburg, Wurzburg, Germany.
Johannes M Haydn
Birgit Samans
Michael Krause
Martin Eilers
Manfred Schartl
Svenja Meierjohann
University of Würzburg · DEInstitute of Molecular Biology · DEUniversity of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelanoma is an aggressive tumor with increasing incidence. To develop accurate prognostic markers and targeted therapies, changes leading to malignant transformation of melanocytes need to be understood. In the Xiphophorus melanoma model system, a mutated version of the EGF receptor Xmrk (Xiphophorus melanoma receptor kinase) triggers melanomagenesis. Cellular events downstream of Xmrk, such as the activation of Akt, Ras, B-Raf or Stat5, were also shown to play a role in human melanomagenesis. This makes the elucidation of Xmrk downstream targets a useful method for identifying processes involved in melanoma formation.

methodsHere, we analyzed Xmrk-induced gene expression using a microarray approach. Several highly expressed genes were confirmed by realtime PCR, and pathways responsible for their induction were revealed using small molecule inhibitors. The expression of these genes was also monitored in human melanoma cell lines, and the target gene FOSL1 was knocked down by siRNA. Proliferation and migration of siRNA-treated melanoma cell lines were then investigated.

resultsGenes with the strongest upregulation after receptor activation were FOS-like antigen 1 (Fosl1), early growth response 1 (Egr1), osteopontin (Opn), insulin-like growth factor binding protein 3 (Igfbp3), dual-specificity phosphatase 4 (Dusp4), and tumor-associated antigen L6 (Taal6). Interestingly, most genes were blocked in presence of a SRC kinase inhibitor. Importantly, we found that FOSL1, OPN, IGFBP3, DUSP4, and TAAL6 also exhibited increased expression levels in human melanoma cell lines compared to human melanocytes. Knockdown of FOSL1 in human melanoma cell lines reduced their proliferation and migration.

conclusionAltogether, the data show that the receptor tyrosine kinase Xmrk is a useful tool in the identification of target genes that are commonly expressed in Xmrk-transgenic melanocytes and melanoma cell lines. The identified molecules constitute new possible molecular players in melanoma development. Specifically, a role of FOSL1 in melanomagenic processes is demonstrated. These data are the basis for future detailed analyses of the investigated target genes.

Indexed as

Gene Expression ProfilingAnimalsBiomarkers, TumorBlotting, WesternCell AdhesionCell MovementCell ProliferationCells, CulturedEnzyme ActivationFos-Related Antigen 1HumansMelanocytesMelanomaMiceOligonucleotide Array Sequence AnalysisProto-Oncogene Proteins c-fosBiomarkers, TumorFos-Related Antigen 1Proto-Oncogene Proteins c-fosReceptor Protein-Tyrosine KinasesRNA, MessengerRNA, Small Interfering

Identifiers

PMID20663135
PMCPMC2912872
OpenAlexW2123086259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.